BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ox.ac.uk//NONSGML oxford.event//EN
X-WR-TIMEZONE:Europe/London
BEGIN:VTIMEZONE
TZID:Europe/London
X-LIC-LOCATION:Europe/London
BEGIN:DAYLIGHT
DTSTART:19700329T010000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
TZNAME:BST
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:19701025T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
TZNAME:GMT
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
SUMMARY:IDEU Seminar - Early measles vaccination in Ugandan infants – an
  RCT
DTSTART;TZID=Europe/London:20260511T130000
DTEND;TZID=Europe/London:20260511T140000
DTSTAMP:20260508T151924Z
UID:5096d98d-6219-f111-8342-7c1e522d9057
CREATED:20260306T135801Z
DESCRIPTION:Summary: Measles remains a major cause of illness and death in
  Africa\, despite the wide availability of a safe\, effective\, low-cost v
 accine. The World Health Organization (WHO) recommends two doses of measle
 s vaccine\, with the first given at nine months of age or later.\n\nMatern
 al antibodies protect infants at birth but typically wane by six months of
  age\, leaving a window before the nine-month vaccine schedule begins. Thi
 s is a period of elevated risk for infection and serious complications.\n\
 nGiving the vaccine earlier\, at six months of age\, may not produce as st
 rong an immune response but could still offer better protection than waiti
 ng until 9 months of age\, especially in high-risk settings. However\, evi
 dence to guide decision-making for measles vaccine policy is lacking.\n\nT
 his talk will present the early results from a clinical trial in Ugandan i
 nfants comparing early (6+12 months) versus standard (9+18 months) dosing 
 schedules.\n\n\nBio: Merryn Voysey is Professor of Statistics in Vaccinolo
 gy at the Oxford Vaccine Group. She has extensive experience in leading va
 ccines research including clinical trials and observational studies\, and 
 was the lead methodologist for the Oxford-AstraZeneca vaccine trials. \n\n
 Merryn is the Principal Investigator of a global study of measles seroprev
 alence in infants from 9 countries\, and is Chief Investigator of a random
 ised controlled trial assessing the early administration of measles vaccin
 ation in Ugandan infants. With funding from the Bill & Melinda Gates Found
 ation\, she is principal investigator of studies investigating the contrib
 ution of T-cell immunity to protection against SARS-CoV-2 infection\, corr
 elates of protection and vaccine efficacy for Group B streptococcus vaccin
 es\, and a study of pneumococcal vaccine seroefficacy. In addition\, she i
 s co-investigator on the EDCTP3 funded PROTECT study: Preparing for Optima
 l Phase III/IV maternal Group B Streptococcal vaccine trials in Africa.\n\
 nMerryn serves on the following committees: The UK Commission on Human Med
 icines Expert Advisory Group on Clinical Trials\, Biologicals and Vaccines
 \; the WHO Technical Advisory Group on Group B Streptococcus Vaccine Devel
 opment\; the UK JCVI Subcommittee on GBS Vaccines\; and the NIHR Health Te
 chnology Assessment Funding Committee. Additionally she chairs the Departm
 ent of Paediatrics Athena Swan Data subcommittee.\n\nIn 2022 Merryn was aw
 arded Australian of the Year in the UK by the Australian High Commission a
 nd was a guest of the Australian Government at Westminster Abbey for the C
 oronation of King Charles III.
LAST-MODIFIED:20260428T081108Z
LOCATION:Big Data Institute\, Big Data Institute Old Road Campus  Oxford O
 xfordshire OX3 7LF United Kingdom
SPEAKER:Professor Merryn Voysey
END:VEVENT
END:VCALENDAR